Bdr Pharma
- All
- News
- Videos
-
BDR Pharma Gets DRDO Nod To Manufacture, Sell Covid Drug 2-DG In India
BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country.
-
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
-
Pharma giant Novartis waits nervously on Glivec drug patent verdict today
Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.
-
BDR seeks compulsory licence for cancer drug; offers 95 per cent cheaper generic copy
Drug firm BDR Pharmaceuticals has applied for a compulsory licence to market generic version of US-based Bristol-Myers Squibb's cancer drug Dasatinib, sold under 'Sprycel' brand, promising to offer the product at price cheaper by over 95 per cent for a month's treatment.
-
BDR Pharma seeks license to sell version of a cancer drug
BDR Pharmaceuticals International Pvt Ltd has applied to the patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, Dasatinib, through a so-called compulsory license mechanism, a BDR executive said on Monday.
-
BDR Pharma Gets DRDO Nod To Manufacture, Sell Covid Drug 2-DG In India
BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country.
-
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
-
Pharma giant Novartis waits nervously on Glivec drug patent verdict today
Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.
-
BDR seeks compulsory licence for cancer drug; offers 95 per cent cheaper generic copy
Drug firm BDR Pharmaceuticals has applied for a compulsory licence to market generic version of US-based Bristol-Myers Squibb's cancer drug Dasatinib, sold under 'Sprycel' brand, promising to offer the product at price cheaper by over 95 per cent for a month's treatment.
-
BDR Pharma seeks license to sell version of a cancer drug
BDR Pharmaceuticals International Pvt Ltd has applied to the patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, Dasatinib, through a so-called compulsory license mechanism, a BDR executive said on Monday.
